Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (9656)	12/5/2003 10:23:47 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

MOGN strong today on an increase in estimates from Merrill Lynch (thanks WK). Turns out that for the next few years at least Aloxi use will be substantially more profitable for hospitals and doctors under Medicare than will the competitive drugs. ML raised their peak sales to $450m from $350m. I have to believe that the combination of being both a better drug and being a more profitable drug for physicians to use (at least under Medicare, which is about 40% of the cancer market) will provide even more explosive growth next year than is being predicted. I added some recently, although this is already my third biggest position (after SEPR and AMEV). Peter